Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
GlucoTrack, Inc. Market Cap
The GlucoTrack, Inc. (GCTK) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered GCTK. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for GCTK is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
GlucoTrack, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that GlucoTrack, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of GCTK.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
N/A
Staff Count
6
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Market Cap
$14.5M
In 2023, GCTK generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that GCTK's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 12 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Rutherford, NJ, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (u201cGlucotracku201d or the u201cCompanyu201d), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has achieved another milestone in its development of an implantable continuous glucose monitor (CGM) by commencing preclinical animal testing.
Thu, 31 Aug 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Rutherford, NJ, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (u201cGlucotracku201d or the u201cCompanyu201d), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has appointed Erin Carter to its Board of Directors and as Chair of its Audit Committee, effective immediately.
Mon, 28 Aug 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Rutherford, NJ, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (u201cGlucotracku201d or the u201cCompanyu201d), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Drinda Benjamin has joined the company as Vice President of Marketing.
Tue, 25 Jul 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Rutherford, NJ, July 25, 2023 (GLOBE NEWSWIRE) -- - Glucotrack, Inc. (Nasdaq: GCTK) (u201cGlucotracku201d or the u201cCompanyu201d), a medical device and digital health platform company focused on diabetes and prediabetes, announced today the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes.
Mon, 17 Apr 2023
Sentiment - NEUTRAL
Source - Accesswire
Summary - NEW YORK, NY / ACCESSWIRE / April 17, 2023 / Aegis Capital Corp. acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ:GCTK). About GlucoTrack, Inc. GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally.
Mon, 17 Apr 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Rutherford, NJ, April 17, 2023 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (u201cGlucoTracku201d or the u201cCompanyu201d), a medical device and digital health platform company focused on diabetes and prediabetes, announced the closing of a firm commitment underwritten public offering of shares of its common stock with gross proceeds to the Company expected to be approximately $10.0 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The offering consisted of 7,352,942 shares of common stock and pre-funded warrants to purchase shares of common stock at a price to the public of $1.36 per share (less $0.001 in exercise price per pre-funded warrant).
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
